Deutsch English Français

Contact

EP2383573

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2383573

EP2383573 - SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 20.09.2013 Database last updated on 16.09.2024
Most recent event Tooltip	20.09.2013	Application deemed to be withdrawn	published on 23.10.2013 [2013/43]
Applicant(s)	For all designated states Astellas Pharma Inc. 3-11, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP
	[2011/44]
Inventor(s)	01 / FURUTANI, Takashi c/o Astellas Pharma Inc. 3-11 Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP
	02 / ENJO, Kentaro c/o Astellas Pharma Inc. 3-11 Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP
	03 / KIKUCHI, Aya c/o Astellas Pharma Inc. 3-11 Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP
	04 / KUROMITSU, Sadao c/o Astellas Pharma Inc. 3-11 Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP
	05 / IDEYAMA, Yukitaka c/o Astellas Pharma Inc. 3-11 Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP
	06 / SUZUKI, Tomoyuki c/o Astellas Pharma Inc. 3-11 Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP
	07 / KURIHARA, Ryoko c/o Astellas Pharma Inc. 3-11 Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 / JP
	[2011/44]
Representative(s)	Bates, Philip Ian Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
	[N/P]
Former [2011/44]	Bates, Philip Ian Reddie & Grose 16 Theobalds Road London WC1X 8PL / GB
Application number, filing date	10735787.3	26.01.2010
	WO2010JP50937
Priority number, date	JP20090015118	27.01.2009 Original published format: JP 2009015118
	[2011/44]
Filing language	JA
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010087319
	Date:	05.08.2010
	Language:	JA
	[2010/31]
	Type:	A1 Application with search report
	No.:	EP2383573
	Date:	02.11.2011
	Language:	EN
	[2011/44]
Search report(s)	International search report - published on:	JP	05.08.2010
	(Supplementary) European search report - dispatched on:	EP	24.09.2012
Classification	IPC:	G01N33/50, A61K45/00, A61P31/00, G01N33/15	[2011/44]
	CPC:	G01N33/5017 (EP,US); A61P13/08 (EP); A61P31/00 (EP); A61P35/00 (EP); A61P43/00 (EP); A61P5/28 (EP); (+) G01N33/57434 (EP,US); G01N2333/904 (EP,US); Y10T436/200833 (EP,US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR
Title	German:	SCREENING-VERFAHREN FÜR EINE ALS MITTEL ZUR BEHANDLUNG VON PROSTATAKREBS VERWENDBARE SUBSTANZ	[2011/44]
	English:	SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER	[2011/44]
	French:	PROCÉDÉ DE CRIBLAGE DE SUBSTANCE UTILE EN TANT QU'AGENT POUR LE CANCER DE LA PROSTATE	[2011/44]
Entry into regional phase	12.04.2011	Translation filed
	28.07.2011	National basic fee paid
	28.07.2011	Search fee paid
	28.07.2011	Designation fee(s) paid
	28.07.2011	Examination fee paid
Examination procedure	28.07.2011	Examination requested [2011/44]
	23.04.2013	Application deemed to be withdrawn, date of legal effect [2013/43]
	10.06.2013	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2013/43]
Fees paid	Renewal fee
	04.11.2011	Renewal fee patent year 03
	10.01.2013	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]EP1990335 (ASTELLAS PHARMA INC [JP]) [X] 6-8 * claims 1-41 *;
		[X] - DAY J M ET AL, "Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase Type 3", MOLECULAR AND CELLULAR ENDOCRINOLOGY, ELSEVIER IRELAND LTD, IE, vol. 301, no. 1-2, doi:10.1016/J.MCE.2008.08.014, ISSN 0303-7207, (20080822), pages 251 - 258, (20080822), XP025953176 [X] 1-8 * the whole document * DOI: http://dx.doi.org/10.1016/j.mce.2008.08.014
		[T] - DANIELA SCHUSTER ET AL, "Identification of chemically diverse, novel inhibitors of 17-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 125, no. 1, doi:10.1016/J.JSBMB.2011.01.016, ISSN 0960-0760, (20110128), pages 148 - 161, (20110205), XP028088733 [T] * the whole document * * table 8 * DOI: http://dx.doi.org/10.1016/j.jsbmb.2011.01.016
	International search	[A]WO2007100066 (ASTELLAS PHARMA INC [JP], et al);
		[A]WO2008149521 (IMMUNO BIOLOG LABOLATORIES CO [JP], et al);
		[A]JPH08512292 (THE UNITED STATES OF AMERICA)
	by applicant	WO9946279
		WO2004006473
		WO03057670
		US2007105862
		WO0107020
		WO2006041874
		EP0563001
		EP0616807
		US5554630
		WO9633194
		WO9817651
		WO9834923
		JPH07133224
		WO9733872
		JP2002193947
		WO2008006790
		- THE NEW ENGLAND JOURNAL OF MEDICINE, (2003), vol. 349, pages 2387 - 2398
		- FRONTIER IN NEUROENDOCRINOLOGY, (2001), vol. 22, pages 185 - 212
		- THE JOURNAL OF UROLOGY, (1999), vol. 161, pages 332 - 337
		- THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, (1995), vol. 80, pages 1066 - 1071
		- CLINICAL CANCER RESEARCH, (2004), vol. 10, pages 440 - 448
		- STEROIDS, (2004), vol. 69, pages 795 - 801
		- CANCER RESEARCH, (2006), vol. 66, pages 2815 - 2825
		- NATURE GENETICS, (1994), vol. 7, pages 34 - 39
		- ENDOCRINE REVIEWS, (2003), vol. 24, pages 152 - 182
		- THE JOURNAL OF BIOLOGICAL CHEMISTRY, (2002), vol. 277, no. 27, pages 24799 - 24808
		- CARCINOGENESIS, (2004), vol. 25, no. 11, pages 2177 - 2181
		- CANCER RESEARCH, (2004), vol. 64, pages 1802 - 1810
		- MOLECULAR AND CELLULAR ENDOCRINOLOGY, (2006), vol. 248, pages 233 - 235
		- THE JOURNAL OF MEDICINAL CHEMISTRY, (1998), vol. 41, no. 27, pages 5457 - 5465
		- BIOORGANIC AND MEDICINAL CHEMISTRY, (2004), vol. 12, no. 15, pages 4009 - 4015
		- BIOORGANIC AND MEDICINAL CHEMISTRY, (2005), vol. 13, no. 24, pages 6598 - 6608
		- CANCER RESEARCH, (1996), vol. 56, pages 3042 - 3046
		- JOURNAL OF STEROID BIOCHEMISTRY, (1988), vol. 30, pages 311 - 314
		- PROG. MED., (1985), vol. 5, pages 2157 - 2161
		- "Drug Design", Pharmaceutical Research and Development, HIROKAWA PUBLISHING COMPANY, (1990), vol. 7, pages 163 - 198
		- The fourth edition of Courses in Experimental Chemistry (Vol. 20), MARUZEN, (1992), vol. 20
		- The fifth edition of Courses in Experimental Chemistry, MARUZEN, (2005), vol. 14
		- COMPENDIUM OF ORGANIC SYNTHETIC METHODS, vol. 1-3
		- The fourth edition of Courses in Experimental Chemistry (VoL 26), MARUZEN, (1992), vol. 26
		- SYNTHESIS, (1982), vol. 10, pages 876 - 878
		- The fourth edition of Courses in Experimental Chemistry (Vol 22), MARUZEN, (1992), vol. 22
		- The fifth edition of Courses in Experimental Chemistry (Vol. 16), MARUZEN, (2005), vol. 16
		- JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (2001), vol. 123, pages 7727 - 7729
		- The fourth eddition of Courses in Experimental Chemistry (Vol. 26), MARUZEN, (1992), vol. 26
		- MOLECULAR ENDOCRINOLOGY, (1997), vol. 11, no. 13, pages 1971 - 1984
		- TREVOR M. PENNING, BIOCHEM. J., (2000), vol. 351, pages 67 - 77

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p